All RA cases n=13 505 | Seropositive RA* n=9255 (68.5%) | Seronegative RA* n=3866 (28.6%) | |
Female, n (%) | 9113 (67.5) | 6511 (70.4) | 2339 (60.5) |
Age, years, median (IQR) | 62.1 (20.8) | 60.8 (20.8) | 65.0 (20.0) |
Educational level† | |||
≤9 years, n (%) | 3652 (27.2) | 2414 (26.3) | 1137 (29.6) |
10–12 years, n (%) | 6161 (45.9) | 4267 (46.5) | 1704 (44.3) |
>12 years, n (%) | 3598 (26.8) | 2503 (27.3) | 1005 (26.1) |
Smoking‡, n (%) | 6893 (60.0) | 5002 (62.1) | 1698 (54.3) |
Treatment at RA diagnosis | |||
MTX monotherapy, n (%) | 9178 (68.0) | 6199 (67.0) | 2724 (70.5) |
Non-MTX csDMARDs, n (%) | 768 (5.7) | 506 (5.5) | 245 (6.3) |
MTX+other csDMARDs, n (%) | 101 (0.8) | 63 (0.7) | 29 (0.8) |
b/tsDMARDs, n (%) | 339 (2.5) | 270 (2.9) | 58 (1.5) |
No treatment, n (%) | 3119 (23.1) | 2217 (24.0) | 810 (21.0) |
*Missing information on serological status: 384 (2.8%).
†Missing information on educational level: 94 (0.7%).
‡Current or previous smoking. Missing information on smoking: all RA cases: 2007 (14.9%), seropositive RA: 1195 (12.9%), seronegative RA: 739 (19.1%).
b/tsDMARDs, biological/targeted synthetic disease-modifying antirheumatic drugs; csDMARDs, conventional synthetic disease-modifying antirheumatic drugs; MTX, methotrexate; RA, rheumatoid arthritis.